The Parathyroids
Basic and Clinical Concepts
- 4th Edition - December 1, 2029
- Latest edition
- Editors: John P. Bilezikian, Robert Marcus, Michael A. Levine, Claudio Marcocci, Shonni J Silverberg, John T. Potts, Jasna Markovac
- Language: English
- Hardback ISBN:9 7 8 - 0 - 1 2 - 8 2 1 8 5 1 - 8
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 2 2 6 2 9 - 2
Praise for Previous Editions: "...a comprehensive source of information that most endocrinologists will want to have on their bookshelves." --Trends in Endocrinology and Metaboli… Read more
Purchase options
Praise for Previous Editions:
"...a comprehensive source of information that most endocrinologists will want to have on their bookshelves." --Trends in Endocrinology and Metabolism, 2003
"It represents a significant contribution to the field, and likely will continue to do so for many editions." --Bart L. Clarke, Mayo Clinic, for Doody Publishing Reviews, 2002
Written by world experts, The Parathyroids, Fourth Edition is thoroughly updated to reflect the considerable advances in just about every aspect of parathyroid biology. It continues to be the authoritative reference that spans the basic science of parathyroid hormone treatment to major clinical disorders in a superb, single compendium. This translational resource is invaluable to graduate students, fellows, researchers, and research clinicians in the fields of endocrinology, bone biology, osteology, nephrology, and rheumatology. Since the publication of the previous edition, interest in hypoparathyroidism has intensified with new insights into etiology, epidemiology, molecular genetics, and therapeutics.
- Includes updated information about hypoparathyroidism, reflecting advances in the field, as well as an update on the full coverage of hyperparathyroidism.
- SUMMARIZES THE LATEST RESEARCH AND TRANSLATIONAL PROGRESS IN THE CLINICAL MANAGEMENT OF PARATHYROID HORMONE DISORDERS
- OFFERS NEW INSIGHTS INTO THE IMPORTANT CAUSES OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE, FRACTURE HEALING, AND VASCULAR DISEASE
- INCORPORATES NEW CHAPTERS AND INFORMATION ADVANCES IN GENETICS AND GENOMICS
- INCLUDES ESSENTIAL UPDATES ON THE CRITICAL IMPORTANCE OF VITAMIN D INSUFFICIENCY AND ITS RELATIONSHIP TO SECONDARY HYPERPARATHYROIDISM
Biomedical researchers, research clinicians, graduate students, and fellows in the fields of endocrinology, bone biology, osteology, and rheumatology.
Section I: Molecular, Cellular, and Physiologic Aspects of The Parathyroids
Introduction - A History of the Parathyroid Glands and their Secretory Product, Parathyroid Hormone
Chapter 1 - Parathyroids: Morphology and Pathology
Chapter 2 - Parathyroid Hormone Gene: Structure, Evolution, and Regulation
Chapter 3 - Parathyroid Hormone-related Protein: Gene Structure, Biosynthesis, Metabolism and Regulation
Chapter 4 - Interactions of PTH with Receptors and Signaling
Chapter 5 - Interactions of PTHrP with Receptors and Signaling
Chapter 6 - Control of Parathyroid Hormone Secretion by its Key Physiological Regulators
Chapter 7 - Molecular Actions of Parathyroid Hormone
Chapter 8 - Cellular Actions of PTH: Osteoblasts, Osteoclasts, and Osteocytes
Chapter 9 - Physiologic Actions of PTH I: PTH Action on the Skeleton
Chapter 10 - Physiological Actions of PTH II: Renal Actions
Chapter 11 - Physiological Actions of PTH and PTHrP III: Endochondral Bone Formation
Chapter 12 - Physiological Actions of PTH and PTHrP IV: Vascular, Cardiovascular, and CNS Biology
Chapter 13 - Physiological Actions of Parathyroid Hormone (PTH) and PTH-related Protein:Epidermal, Mammary, Reproductive, and Pancreatic Tissues
Chapter 14 - PTH and T-cell Biology
Chapter 15 - Anabolic and Catabolic Pathways of Parathyroid Hormone on the Skeleton
Chapter 16 - Metabolism and Measurement of Parathyroid Hormone
Section II: Clinical Aspects of Primary Hyperparathyroidism
Chapter 17 - Parathyroid Growth: Normal and Abnormal
Chapter 18 - Molecular Basis of Primary Hyperparathyroidism
Chapter 19 - Epidemiology of Primary Hyperparathyroidism
Chapter 20 - Clinical Presentation of Primary Hyperparathyroidism: A Global Perspective
Chapter 21 - Asymptomatic Primary Hyperparathyroidism
Chapter 22 - Normocalcemic PHPT
Chapter 23 - Familial and Hereditary Forms of Primary Hyperparathyroidism
Chapter 24 - Familial Hypocalciuric Hypercalcemia and Neonatal Severe Hyperparathyroidism
Chapter 25 - Primary Hyperparathyroidism in Children and Adolescents
Chapter 26 - Acute Primary Hyperparathyroidism
Chapter 27 - Parathyroid Carcinoma
Chapter 28 - Bone Turnover Markers in Primary Hyperparathyroidism
Chapter 29 - Bone Histomorphometry and Bone Quality in Primary Hyperparathyroidism
Chapter 30 - Skeletal Imaging in Primary Hyperparathyroidism
Chapter 31 - Primary Hyperparathyroidism and the Kidney
Chapter 32 - Non-traditional Manifestations of Primary Hyperparathyroidism
Chapter 33 - Vitamin D and Primary Hyperparathyroidism
Chapter 34 - Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism
Chapter 35 - Preoperative Localization of Abnormal Parathyroid Glands
Chapter 36 - Surgical Management of Primary Hyperparathyroidism
Chapter 37 - Medical Management of Primary Hyperparathyroidism
Section III: Non-Parathyroid Hypercalcemic States
Chapter 38 - Hypercalcemia Due to PTHrP
Chapter 39 - Hypercalcemia Associated with Local and Ectopic Hormone Production
Chapter 40 - Genetic Disorders Caused by Mutations in the PTH/PTHrP Receptor and Downstream Effector Molecules
Chapter 41 - The Differential Diagnosis of Hypercalcemia
Chapter 42 - Acute Management of Hypercalcemia
Section IV: Secondary and Tertiary Hyperparathyroid States
Chapter 43 - Vitamin D and Parathyroid Hormone
Chapter 44 - The Parathyroids in Renal Disease: Pathophysiology and Systemic Consequences
Chapter 45 - Clinical Skeletal Syndromes Associated with Parathyroid Disorders in Chronic Kidney Disease
Chapter 46 - Other Secondary Hyperparathyroid States
Section V: The Hypoparathyroid States
Chapter 47 - Hypoparathyroidism in the Differential Diagnosis of Hypocalcemia
Chapter 48 - Magnesium Depletion and Parathyroid Function
Chapter 49 - Epidemiology of Hypoparathyroidism
Chapter 50 - The Molecular Genetics of Hypoparathyroidism
Chapter 51 - Surgical Hypoparathyroidism
Chapter 52 - Autoimmune Hypoparathyroidism
Chapter 53 - Clinical Manifestations of Hypoparathyroidism
Chapter 54 - Skeletal Manifestations of Hypoparathyroidism
Chapter 55 - Molecular and Clinical Aspects of Pseudohypoparathyroidism
Chapter 56 - Treatment of Hypoparathyroidism with Calcium and Vitamin D
Chapter 57 - Treatment of Hypoparathyroidism with Parathyroid Hormone
Section VI: The Parathyroids and Osteoporosis
Chapter 58 - Parathyroid Hormone in the Pathophysiology of Osteoporosis
Chapter 59 - Parathyroid Hormone and Glucocorticoid-induced Osteoporosis
Chapter 60 - Parathyroid Hormone as Monotherapy for the Treatment of Osteoporosis
Chapter 61 - Combination Osteoporosis Therapy with Parathyroid Hormone
Chapter 62 - The Role of Parathyroid Hormone in Fracture Healing
Chapter 63 - Parathyroid Function and Disease during Pregnancy, Lactation, and Fetal/Neonatal Development
Introduction - A History of the Parathyroid Glands and their Secretory Product, Parathyroid Hormone
Chapter 1 - Parathyroids: Morphology and Pathology
Chapter 2 - Parathyroid Hormone Gene: Structure, Evolution, and Regulation
Chapter 3 - Parathyroid Hormone-related Protein: Gene Structure, Biosynthesis, Metabolism and Regulation
Chapter 4 - Interactions of PTH with Receptors and Signaling
Chapter 5 - Interactions of PTHrP with Receptors and Signaling
Chapter 6 - Control of Parathyroid Hormone Secretion by its Key Physiological Regulators
Chapter 7 - Molecular Actions of Parathyroid Hormone
Chapter 8 - Cellular Actions of PTH: Osteoblasts, Osteoclasts, and Osteocytes
Chapter 9 - Physiologic Actions of PTH I: PTH Action on the Skeleton
Chapter 10 - Physiological Actions of PTH II: Renal Actions
Chapter 11 - Physiological Actions of PTH and PTHrP III: Endochondral Bone Formation
Chapter 12 - Physiological Actions of PTH and PTHrP IV: Vascular, Cardiovascular, and CNS Biology
Chapter 13 - Physiological Actions of Parathyroid Hormone (PTH) and PTH-related Protein:Epidermal, Mammary, Reproductive, and Pancreatic Tissues
Chapter 14 - PTH and T-cell Biology
Chapter 15 - Anabolic and Catabolic Pathways of Parathyroid Hormone on the Skeleton
Chapter 16 - Metabolism and Measurement of Parathyroid Hormone
Section II: Clinical Aspects of Primary Hyperparathyroidism
Chapter 17 - Parathyroid Growth: Normal and Abnormal
Chapter 18 - Molecular Basis of Primary Hyperparathyroidism
Chapter 19 - Epidemiology of Primary Hyperparathyroidism
Chapter 20 - Clinical Presentation of Primary Hyperparathyroidism: A Global Perspective
Chapter 21 - Asymptomatic Primary Hyperparathyroidism
Chapter 22 - Normocalcemic PHPT
Chapter 23 - Familial and Hereditary Forms of Primary Hyperparathyroidism
Chapter 24 - Familial Hypocalciuric Hypercalcemia and Neonatal Severe Hyperparathyroidism
Chapter 25 - Primary Hyperparathyroidism in Children and Adolescents
Chapter 26 - Acute Primary Hyperparathyroidism
Chapter 27 - Parathyroid Carcinoma
Chapter 28 - Bone Turnover Markers in Primary Hyperparathyroidism
Chapter 29 - Bone Histomorphometry and Bone Quality in Primary Hyperparathyroidism
Chapter 30 - Skeletal Imaging in Primary Hyperparathyroidism
Chapter 31 - Primary Hyperparathyroidism and the Kidney
Chapter 32 - Non-traditional Manifestations of Primary Hyperparathyroidism
Chapter 33 - Vitamin D and Primary Hyperparathyroidism
Chapter 34 - Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism
Chapter 35 - Preoperative Localization of Abnormal Parathyroid Glands
Chapter 36 - Surgical Management of Primary Hyperparathyroidism
Chapter 37 - Medical Management of Primary Hyperparathyroidism
Section III: Non-Parathyroid Hypercalcemic States
Chapter 38 - Hypercalcemia Due to PTHrP
Chapter 39 - Hypercalcemia Associated with Local and Ectopic Hormone Production
Chapter 40 - Genetic Disorders Caused by Mutations in the PTH/PTHrP Receptor and Downstream Effector Molecules
Chapter 41 - The Differential Diagnosis of Hypercalcemia
Chapter 42 - Acute Management of Hypercalcemia
Section IV: Secondary and Tertiary Hyperparathyroid States
Chapter 43 - Vitamin D and Parathyroid Hormone
Chapter 44 - The Parathyroids in Renal Disease: Pathophysiology and Systemic Consequences
Chapter 45 - Clinical Skeletal Syndromes Associated with Parathyroid Disorders in Chronic Kidney Disease
Chapter 46 - Other Secondary Hyperparathyroid States
Section V: The Hypoparathyroid States
Chapter 47 - Hypoparathyroidism in the Differential Diagnosis of Hypocalcemia
Chapter 48 - Magnesium Depletion and Parathyroid Function
Chapter 49 - Epidemiology of Hypoparathyroidism
Chapter 50 - The Molecular Genetics of Hypoparathyroidism
Chapter 51 - Surgical Hypoparathyroidism
Chapter 52 - Autoimmune Hypoparathyroidism
Chapter 53 - Clinical Manifestations of Hypoparathyroidism
Chapter 54 - Skeletal Manifestations of Hypoparathyroidism
Chapter 55 - Molecular and Clinical Aspects of Pseudohypoparathyroidism
Chapter 56 - Treatment of Hypoparathyroidism with Calcium and Vitamin D
Chapter 57 - Treatment of Hypoparathyroidism with Parathyroid Hormone
Section VI: The Parathyroids and Osteoporosis
Chapter 58 - Parathyroid Hormone in the Pathophysiology of Osteoporosis
Chapter 59 - Parathyroid Hormone and Glucocorticoid-induced Osteoporosis
Chapter 60 - Parathyroid Hormone as Monotherapy for the Treatment of Osteoporosis
Chapter 61 - Combination Osteoporosis Therapy with Parathyroid Hormone
Chapter 62 - The Role of Parathyroid Hormone in Fracture Healing
Chapter 63 - Parathyroid Function and Disease during Pregnancy, Lactation, and Fetal/Neonatal Development
- Edition: 4
- Latest edition
- Published: December 1, 2029
- Language: English
JB
John P. Bilezikian
Dr. John P. Bilezikian, the Dorothy L. and Daniel H. Silberberg Professor of Medicine and Professor of Pharmacology at the College of Physicians & Surgeons, Columbia University is Chief of the Division of Endocrinology and Director of the Metabolic Bone Diseases Program at Columbia University Medical Center. Dr. Bilezikian received his undergraduate training at Harvard College and his medical training at the College of Physicians & Surgeons. He completed four years of house staff training (internship, residency and Chief Residency) on the Medical Service at Columbia Presbyterian Medical Center. Dr. Bilezikian received his training in Metabolic Bone Diseases and in Endocrinology at the NIH in the Mineral Metabolism Branch under the tutelage of Dr. Gerald Aurbach.
Affiliations and expertise
Chief, Division of Endocrinology; Director, Metabolic Bone Diseases Program, Departments of Medicine and Pharmacology, College of Physicians and Surgeons, Columbia University, New York, NY, USARM
Robert Marcus
Dr. Marcus is Professor-Emeritus, Stanford University, where he served on the full-time medical faculty for almost 25 years, before joining the Emeritus faculty in 2001. At Stanford, he was located at the Veterans Affairs Medical Center, Palo Alto California, where he served as Director of the Aging Study Unit of the Geriatrics Research, Education, & Clinical Center from 1982-2001. Dr. Marcus enjoyed a long career as a clinical investigator in the fields of bone and mineral metabolism and osteoporosis medicine. His own research interests included diagnosis and therapy of primary hyperpara-thyroidism, interactions of the parathyroid-vitamin D axis with estrogen, age-related changes in the growth hormone-IGF axis, effects of growth hormone replacement for older men and women, metabolic and musculoskeletal effects of resistance exercise in older men and women, adolescent bone acquisition, and osteoporosis therapeutics. Dr. Marcus’ laboratory was a study site for many of the pivotal clinical trials in the osteoporosis field. These include the NIH Post-menopausal Estrogen/Progestin Interventions Trial (PEPI), Merck’s Fracture Intervention Trial (FIT), Lilly’s Multiple Outcomes of Raloxifene Intervention (MORE), and Lilly’s registration trial of recombinant PTH(1-34) in the treatment of postmenopausal women with osteoporosis. In 2001. Dr. Marcus joined the US Affiliate of Eli Lilly & Company to support Lilly’s program in Osteoporosis and Skeletal Medicine. From 2003 until his retirement from Lilly in 2008, Dr. Marcus was the lead physician for the Forteo team at Lilly. He has published more than 150 research papers, editorials, and reviews. Dr. Marcus served as President of the American Society for Bone & Mineral Research in 2000-2001.
Affiliations and expertise
Professor Emeritus, Department of Medicine, Stanford University School of Medicine, CA, USAML
Michael A. Levine
Dr. Michael A. Levine is Chief of Endocrinology and Diabetes and Director of the Center for Bone Health at The Children’s Hospital of Philadelphia. Dr. Levine holds the Lester Baker Endowed Chair and is Professor of Pediatrics and Medicine at the University of Pennsylvania Perelman School of Medicine. Dr. Levine’s research focuses on the genetic basis of disorders of bone and mineral metabolism and complements his clinical expertise in endocrine diseases that affect bone and mineral metabolism. His approach is to apply molecular and genetic tools to analyze the basis of altered hormone action, particularly in G protein-coupled signal transduction systems that affect growth and development. He has identified or contributed to the molecular basis of several inherited disorders of bone and mineral metabolism, including familial hypoparathyroidism, pseudohypoparathyroidism, cherubism, and the McCune Albright syndrome. His research interests now extend to the molecular events that control embryological development of the parathyroid glands and genetic modifiers of vitamin D action.
Affiliations and expertise
Chief of Endocrinology and Diabetes and Director of the Center for Bone Health, The Children’s Hospital of Philadelphia, Philadelphia, PA, USACM
Claudio Marcocci
Claudio Marcocci, MD, is Professor of Endocrinology at the Department of Clinical and Experimental Medicine, Director of the Postgraduate School in Endocrinology and Metabolism, University of Pisa and Director of the Endocrine Unit 2, University Hospital of Pisa. Over the years he has combined its clinical appointments with basic, translational and clinical research in the fields of parathyroid and thyroid diseases and vitamin D. Over the last 10 years he has contributed original work on the management of Graves’ orbitopathy, the calcium sensing receptor, clinical aspects of primary hyperparathyroidism and hypoparathyroidism and the molecular mechanisms of parathyroid tumorigenesis. Member of several Scientific Associations: Italian Society of Endocrinology, Italian Society of Osteoporosis, Mineral Metabolism and Skeletal Diseases, European Thyroid Association, American Thyroid Association, Endocrine Society, American Society of Bone and Mineral Research, American Association of Clinical Endocrinologists.
Affiliations and expertise
Professor of Endocrinology, Department of Endocrinology, Metabolism, and Orthopaedics, University of Pisa, Pisa, ItalySS
Shonni J Silverberg
Shonni J. Silverberg, MD, is an endocrinologist in New York and is affiliated with New York-Presbyterian Hospital-Columbia and Cornell. She received her medical degree from Weill Cornell Medical College of Cornell University and has been in practice for more than 20 years. She is Professor of Clinical Medicine, Division of Endocrinology, Departments of Medicine and Pharmacology, College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Affiliations and expertise
Professor of Clinical Medicine, Division of Endocrinology, Departments of Medicine and Pharmacology, College of Physicians and Surgeons, Columbia University, New York, NY, USAJP
John T. Potts
John T. Potts, Jr., MD, is currently the Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School. After medical training at the University of Pennsylvania, he completed his internship and residency at Massachusetts General Hospital. He went on to work at the National Institutes of Health (NIH), studying protein chemistry with Nobel laureate Christian Anfinsen. Dr. Potts remained at the NIH from 1959 until 1968, when he returned to the MGH as chief of endocrinology. The author or co-author of more than 500 scientific publications, he is a member of the National Academy of Sciences, the Institute of Medicine, and the American Academy of Arts and Sciences. He is also a director of ReceptorBase, Inc. and Zeltiq Aesthetics, a founder of Radius Health, Inc., and a member of the Scientific Advisory Boards of MPM Capital and HealthCare Ventures, as well as the Medical Advisory Board of Cell Genesys
Affiliations and expertise
Distinguished Jackson Professor of Clinical Medicine, Harvard Medical School and The Massachusetts General Hospital, Endocrine Unit, Boston, MA, USAJM
Jasna Markovac
As Publishing Officer in UM’s Health Information Technology and Services, Dr. Markovac is responsible for development and execution of health-related publishing initiatives. She is involved with portfolio development, assessment and analysis of key current and emerging markets for educational, clinical, and research content. She has over 20 years of experience in commercial publishing. Dr. Markovac is Chair, FASEB Publications & Communications Committee and Chair, Career Mentoring and Networking Sub-committee for the Society for Neuroscience.
Affiliations and expertise
Publishing Officer, Health Information Technology and Services, University of Michigan , Ann Arbor, MI, USA